Haifaa Abdulhaq, MD
Hematology/Oncology · Clovis
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Community Health Partners · 497 clinicians in this group
Looking this up.
Hospitals listed: 057248 · Clovis Community Medical Center · Community Regional Medical Center · Kaweah Health Medical Center · Saint Agnes Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Abdulhaq’s office at (559) 387-1900 to ask if they take your plan before you enroll.
California Medical Board record
Licence A111931 · Current
Licensed to practise in California · since 2010 · expires 2028-01-31 · University of Damascus Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Clovis Community Medical CenterClovis, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 80% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.7 (12.1 to 17.7) · 421 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.692, Oct 2024 – Sep 2025
- Community Regional Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 1 of 5 starsWorse than the national rate — Death rate among surgical inpatients with serious treatable complications: 211.21 (174.88 to 247.54) · 239 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.705, Oct 2024 – Sep 2025
- Kaweah Health Medical CenterVisalia, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Kaweah Delta Health Care DistrictPatients rate it 3 of 5 · 67% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — Death rate among surgical inpatients with serious treatable complications: 239.86 (194.11 to 285.6) · 104 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025
- Saint Agnes Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of Trinity Health, which runs 105 hospitals in 16 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.312, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.141, Oct 2024 – Sep 2025
See every measure and the patient survey for Clovis Community Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 0 better, 6 the same, 1 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.7 (12.1 to 17.7) · 421 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.692 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.97 (0.04 to 1.89) · 1,840 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.16 (0.86 to 1.45) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 217.06 (167.45 to 266.67) · 84 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 69 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.1 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.4 · 161 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 14 · 507 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 798 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 336 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 3,771 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.39) · 8,649 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.08 to 0.46) · 9,146 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.46 (1.47 to 5.45) · 1,654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.19 (0.61 to 3.78) · 387 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.18 (0.7 to 3.66) · 1,578 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.47 (7.08 to 19.87) · 374 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.99 (1.37 to 8.61) · 379 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.04) · 405 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.8 (0.23 to 1.38) · 8,198 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 90 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.651 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.922 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.449 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.509 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.3 · 210 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -1.5 · 152 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 58.4 · 556 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18 · 769 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.8 · 802 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (4 to 7.4) · 421 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 91 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 93 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 200 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.8 to 15.6) · 2,398 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 720 cases | No different | Jan 2024 – Dec 2024 |
What patients said (441 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 80% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Community Regional Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 3 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 211.21 (174.88 to 247.54) · 239 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.705 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.13 (0.29 to 1.96) · 2,304 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.09 (0.87 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 116 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.6 · 445 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.2 · 399 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 582 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 3,744 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.5) · 11,052 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,566 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (1.64 to 5.01) · 3,139 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.08 (0 to 2.3) · 1,423 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.7 (0.52 to 2.88) · 3,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.85 (8.11 to 15.6) · 1,481 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.4 (3.81 to 8.98) · 1,404 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.35 (0.95 to 3.76) · 760 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.64 (0.16 to 1.11) · 10,254 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.817 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.031 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.837 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.81 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.853 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 258 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 689 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 37.4 · 202 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 35.2 · 543 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.2 · 434 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.3 · 552 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.6 to 7.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.3 to 15.4) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.4 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.6 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.9 (9.5 to 14.9) · 2,590 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 310 cases | No different | Jan 2024 – Dec 2024 |
What patients said (421 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Kaweah Health Medical Center
Behind the star rating — Deaths: 0 better, 5 the same, 3 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 239.86 (194.11 to 285.6) · 104 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.22 (0.28 to 2.16) · 1,600 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.53 to 1.09) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.4 · 145 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.7 · 226 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.3 · 285 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 14.8 · 626 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 18.1 · 741 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.7 · 373 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.6 · 3,927 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.27 (0.08 to 0.46) · 9,045 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.19 (0.01 to 0.38) · 9,267 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.72 (1.81 to 5.63) · 2,251 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.07 (0.53 to 3.61) · 768 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.79 (0.45 to 3.13) · 2,231 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.88 (1.1 to 12.66) · 799 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 3.59 (0 to 7.19) · 759 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 416 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.35 (0 to 0.89) · 8,159 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 43 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.728 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.405 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.023 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.551 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 344 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.2 · 799 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -17 · 286 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 31.4 · 686 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -6 · 734 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 776 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.6 to 7.6) · 202 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 8.9 (6.6 to 11.9) · 202 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 32 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.6 · 142 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 317 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 10.8 (8.3 to 14) · 1,748 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 680 cases | No different | Jan 2024 – Dec 2024 |
What patients said (435 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Saint Agnes Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 6 the same, 0 worse of 8 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.312 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.141 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.18 to 1.94) · 2,342 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 197.82 (152.64 to 243.01) · 103 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.3 · 300 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.9 · 295 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.8 · 768 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.8 · 969 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 304 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 4,305 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.06 to 0.42) · 11,641 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.07 to 0.43) · 12,213 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.76 (2.91 to 6.61) · 2,466 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.09 (0 to 2.49) · 864 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.61 (0.26 to 2.96) · 2,362 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.1 (5.39 to 14.81) · 900 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.4 (1.2 to 7.59) · 882 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.84 (0.41 to 3.27) · 541 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.67 (0.14 to 1.19) · 9,626 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 58 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.835 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.182 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.004 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 412 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.6 · 1,002 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 28.8 · 296 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 25.5 · 894 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 17.8 · 981 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 1,061 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 13.4 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 412 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.3 (9.6 to 15.9) · 1,324 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 863 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 32% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$228,915
Medicare paid this office $228,915 for 691 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 477 | $138,204 | $95 |
| Long return visit (40+ min) | 125 | $31,675 | $139 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 83 | $18,393 | $93 |
| New patient visit (45+ min) | 80 | $10,221 | $128 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 85 | $8,341 | $95 |
See all 11 services
| Return visit (30+ min) | 477 | $138,204 | $95 |
| Long return visit (40+ min) | 125 | $31,675 | $139 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 83 | $18,393 | $93 |
| New patient visit (45+ min) | 80 | $10,221 | $128 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 85 | $8,341 | $95 |
| Short return visit (20+ min) | 94 | $7,417 | $62 |
| New patient visit (60+ min) | 28 | $4,730 | $169 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $3,780 | $130 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $2,715 | $60 |
| Injection of drug or substance under skin or into muscle | 17 | $649 | $10 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 17 | $56 | None |
Who their Medicare patients are
691 Original Medicare patients in 2024. Average age 72 · Under 65 12% · 85 and older 9% · Women 51% · Also on Medicaid 36% · Health risk score 2.32. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Diabetes 47% · Chronic kidney disease 44% · Coronary heart disease 37% · Heart failure 29% · Cancer 25% · Depression 22% · Atrial fibrillation 20% · COPD 16% · Stroke 13% · Dementia 9%.
The office billed $846,442, Medicare allowed $306,601 and paid $228,915; for 2,440 services of 19 kinds; $56 of it was for drugs given in the office and $228,859 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 691 | 2,440 | 72 | 2.32 | $846,442 | $228,915 |
| 2023 | 560 | 2,213 | 72 | 2.21 | $660,448 | $196,990 |
| 2022 | 470 | 2,043 | 72 | 1.96 | $552,195 | $183,172 |
| 2021 | 430 | 1,717 | 71 | 2.42 | $451,579 | $165,511 |
| 2020 | 422 | 1,711 | 70 | 2.30 | $457,581 | $143,355 |
| 2019 | 463 | 2,136 | 70 | 2.37 | $553,795 | $217,650 |
| 2018 | 311 | 1,480 | 69 | 2.20 | $384,597 | $145,191 |
| 2017 | 284 | 1,593 | 69 | 2.38 | $311,226 | $153,609 |
| 2016 | 261 | 1,033 | 67 | 2.20 | $181,818 | $80,251 |
| 2015 | 261 | 21,020 | 68 | 2.43 | $857,088 | $263,176 |
| 2014 | 333 | 79,650 | 68 | 2.32 | $4,446,694 | $1,365,904 |
| 2013 | 302 | 42,394 | 68 | 2.44 | $2,730,459 | $1,045,522 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Return visit (30+ min) | 408 | $124,176 | $94 |
| Long return visit (40+ min) | 103 | $29,826 | $139 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $12,129 | $93 |
| Short return visit (20+ min) | 105 | $7,203 | $59 |
| New patient visit (45+ min) | 57 | $6,813 | $120 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 43 | $4,379 | $97 |
| New patient visit (60+ min) | 19 | $3,267 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $3,025 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $2,764 | $138 |
| Injection of drug or substance under skin or into muscle | 29 | $1,094 | $10 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 28 | $114 | None |
2022: 12 services
| Return visit (30+ min) | 313 | $105,221 | $95 |
| Long return visit (40+ min) | 95 | $30,946 | $145 |
| Short return visit (20+ min) | 163 | $14,852 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 53 | $8,959 | $83 |
| New patient visit (45+ min) | 46 | $5,254 | $114 |
| New patient visit (60+ min) | 30 | $4,410 | $147 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $4,378 | $156 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 33 | $2,591 | $79 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,855 | $109 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,443 | $58 |
| Injection of drug or substance under skin or into muscle | 49 | $1,169 | $11 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 20 | $78 | None |
2021: 12 services
| Return visit (30+ min) | 244 | $93,887 | $106 |
| Long return visit (40+ min) | 75 | $24,370 | $149 |
| Short return visit (20+ min) | 166 | $19,479 | $73 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 42 | $6,474 | $85 |
| New patient visit (45+ min) | 35 | $4,687 | $134 |
| New patient visit (60+ min) | 19 | $3,371 | $177 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,142 | $157 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 26 | $3,026 | $112 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 27 | $2,153 | $80 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | 57 | $786 | $12 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $771 | $59 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 13 | $78 | None |
2020: 11 services
| Return visit (30+ min) | 254 | $80,123 | $85 |
| Long return visit (40+ min) | 67 | $14,617 | $119 |
| Short return visit (20+ min) | 153 | $11,915 | $55 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 42 | $6,586 | $157 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 54 | $6,156 | $110 |
| New patient visit (45+ min) | 45 | $5,887 | $131 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 37 | $5,849 | $85 |
| New patient visit (60+ min) | 31 | $5,220 | $168 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,003 | $167 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | 61 | $865 | $12 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 14 | $54 | None |
2019: 10 services
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 67 | $75,421 | $157 |
| Return visit (30+ min) | 264 | $74,726 | $84 |
| Long return visit (40+ min) | 74 | $16,453 | $117 |
| Short return visit (20+ min) | 136 | $11,804 | $56 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 100 | $10,898 | $105 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $9,646 | $85 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 34 | $5,497 | $162 |
| New patient visit (60+ min) | 27 | $4,470 | $166 |
| New patient visit (45+ min) | 39 | $4,125 | $106 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,195 | $60 |
2018: 14 services
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 55 | $55,978 | $157 |
| Return visit (30+ min) | 160 | $23,534 | $59 |
| Return visit (30+ min) | 127 | $21,810 | $87 |
| Long return visit (40+ min) | 34 | $6,321 | $115 |
| Long return visit (40+ min) | 42 | $6,286 | $89 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 49 | $5,735 | $110 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $5,230 | $84 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 16 | $4,861 | $157 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,340 | $159 |
| Short return visit (20+ min) | 40 | $2,782 | $59 |
| Short return visit (20+ min) | 59 | $2,598 | $36 |
| New patient visit (60+ min) | 11 | $1,851 | $168 |
| New patient visit (60+ min) | 12 | $1,630 | $136 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $942 | $59 |
2017: 9 services
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 73 | $71,971 | $157 |
| Return visit (30+ min) | 195 | $42,203 | $62 |
| Long return visit (40+ min) | 65 | $12,984 | $88 |
| Short return visit (20+ min) | 77 | $4,264 | $38 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,104 | $164 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 35 | $3,984 | $111 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $3,469 | $85 |
| New patient visit (60+ min) | 15 | $2,046 | $136 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $703 | $59 |
2016: 12 services
| Return visit (30+ min) | 138 | $26,882 | $63 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 34 | $12,230 | $157 |
| Return visit (30+ min) | 57 | $7,640 | $73 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 50 | $5,869 | $111 |
| Long return visit (40+ min) | 39 | $5,638 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $5,246 | $83 |
| Short return visit (20+ min) | 72 | $3,975 | $40 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $3,965 | $159 |
| Short return visit (20+ min) | 29 | $1,937 | $51 |
| New patient visit (60+ min) | 15 | $1,918 | $128 |
| New patient visit (45+ min) | 14 | $1,472 | $105 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $1,418 | $57 |
2015: 15 services
| Return visit (30+ min) | 131 | $47,681 | $81 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 57 | $6,858 | $109 |
| Short return visit (20+ min) | 56 | $5,816 | $58 |
| Long return visit (40+ min) | 37 | $5,625 | $117 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 37 | $4,503 | $83 |
| Injection, zoledronic acid, 1 mg | 16 | $3,488 | None |
| Administration of chemotherapy into vein, 1 hour or less | 18 | $2,667 | $95 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 24 | $2,176 | $52 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,788 | $163 |
| Injection of additional new drug or substance into vein | 22 | $1,594 | $17 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $1,332 | $55 |
| Injection of drug or substance under skin or into muscle | 20 | $1,062 | $19 |
| Injection, granisetron hydrochloride, 100 mcg | 16 | $108 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 15 | $46 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 11 | $9 | None |
2014: 36 services
| Injection, pegfilgrastim, 6 mg | 28 | $151,356 | None |
| Return visit (30+ min) | 125 | $44,601 | $84 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 17 | $40,025 | None |
| Administration of chemotherapy into vein, 1 hour or less | 70 | $28,920 | $109 |
| Injection, zoledronic acid, 1 mg | 20 | $15,510 | None |
| Injection of additional new drug or substance into vein | 83 | $14,821 | $19 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 61 | $11,152 | $84 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 78 | $8,748 | $111 |
| Injection, fosaprepitant, 1 mg | 20 | $8,305 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 47 | $6,693 | $57 |
| Administration of additional new drug or substance into vein, 1 hour or less | 42 | $6,276 | $52 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $6,116 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 34 | $5,885 | $163 |
| Injection of drug or substance under skin or into muscle | 54 | $4,834 | $20 |
| New patient visit (60+ min) | 20 | $3,346 | $167 |
| Administration of chemotherapy into vein, each additional hour | 32 | $3,295 | $23 |
| Long return visit (40+ min) | 21 | $2,585 | $118 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 22 | $2,150 | $15 |
| Administration of additional new drug or substance into vein using push technique | 16 | $1,951 | $51 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $1,861 | $58 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 19 | $1,533 | $25 |
| Infusion into a vein for hydration, 31-60 minutes | 19 | $1,527 | $46 |
| New patient visit (45+ min) | 11 | $1,450 | $132 |
| Infusion into a vein for hydration, each additional hour | 19 | $1,250 | $12 |
| Irrigation of implanted venous access drug delivery device | 15 | $1,060 | $20 |
| Injection, paclitaxel, 30 mg | 12 | $934 | None |
| Short return visit (20+ min) | 14 | $894 | $60 |
| Injection, granisetron hydrochloride, 100 mcg | 61 | $747 | None |
| Injection, carboplatin, 50 mg | 18 | $695 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 72 | $404 | None |
| Injection, etoposide, 10 mg | 12 | $383 | None |
| Injection, ranitidine hydrochloride, 25 mg | 12 | $107 | None |
| Infusion, normal saline solution , 1000 cc | 24 | $80 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 23 | $65 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 33 | $50 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 11 | $31 | None |
2013: 28 services
| Injection, pegfilgrastim, 6 mg | 31 | $183,185 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 16 | $40,935 | None |
| Return visit (30+ min) | 121 | $39,969 | $85 |
| Administration of chemotherapy into vein, 1 hour or less | 67 | $28,630 | $118 |
| Zoldedronic acid 1mg | 13 | $14,410 | $131 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 114 | $14,089 | $108 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 72 | $13,624 | $80 |
| Injection of additional new drug or substance into vein | 76 | $10,733 | $19 |
| Administration of additional new drug or substance into vein, 1 hour or less | 26 | $5,493 | $58 |
| Injection of drug or substance under skin or into muscle | 49 | $5,010 | $22 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,437 | $158 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 23 | $3,885 | $64 |
| Administration of chemotherapy into vein, each additional hour | 31 | $3,872 | $25 |
| New patient visit (60+ min) | 19 | $3,034 | $160 |
| Long return visit (40+ min) | 22 | $2,794 | $116 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 17 | $2,617 | $18 |
| Infusion into a vein for hydration, 31-60 minutes | 19 | $2,600 | $46 |
| Administration of additional new drug or substance into vein using push technique | 15 | $1,801 | $51 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 14 | $1,077 | $27 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $982 | $52 |
| Injection, carboplatin, 50 mg | 19 | $873 | None |
| Infusion into a vein for hydration, each additional hour | 17 | $654 | $13 |
| Injection, ondansetron hydrochloride, per 1 mg | 52 | $355 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 59 | $242 | None |
| Injection, granisetron hydrochloride, 100 mcg | 15 | $189 | None |
| Infusion, normal saline solution , 1000 cc | 23 | $82 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 38 | $56 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 11 | $16 | None |
Medicaid work
$29,241 in 2024
Medicaid paid $29,241 for 2,255 billed services this clinician did in 2024, up to 96 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 846 | $11,201 |
| Long return visit (40+ min) | 134 | $5,453 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 248 | $5,376 |
| COMPREHENSIVE METABOLIC PANEL | 334 | $2,791 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 366 | $2,237 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 45 | $993 |
| Lactate dehydrogenase (LD), (LDH) | 256 | $854 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 26 | $336 |
| 2024 | 2,255 | 8 | 96 | $29,241 |
| 2023 | 3,477 | 12 | 95 | $21,997 |
| 2022 | 3,528 | 14 | 76 | $22,804 |
| 2021 | 2,571 | 11 | 38 | $20,144 |
| 2020 | 753 | 6 | 26 | $9,618 |
| 2019 | 294 | 2 | 25 | $7,906 |
| 2018 | 700 | 6 | 67 | $7,344 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 966 | $7,706 |
| Long return visit (40+ min) | 204 | $3,768 |
| COMPREHENSIVE METABOLIC PANEL | 682 | $3,578 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 693 | $2,648 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 193 | $2,516 |
| Lactate dehydrogenase (LD), (LDH) | 561 | $923 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 34 | $588 |
| Short return visit (20+ min) | 12 | $131 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 13 | $124 |
| Injection, diphenhydramine hcl, up to 50 mg | 16 | $16 |
| Infusion, normal saline solution, 250 cc | 91 | $0 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 12 | $0 |
2022
| COMPREHENSIVE METABOLIC PANEL | 785 | $5,997 |
| Return visit (30+ min) | 671 | $5,705 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 764 | $4,085 |
| Long return visit (40+ min) | 155 | $3,338 |
| Lactate dehydrogenase (LD), (LDH) | 573 | $1,469 |
| Infusion, normal saline solution, 250 cc | 264 | $831 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 35 | $271 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 32 | $256 |
| Short return visit (20+ min) | 102 | $246 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 13 | $194 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 52 | $133 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 53 | $103 |
2021
| COMPREHENSIVE METABOLIC PANEL | 823 | $8,270 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 780 | $5,454 |
| Return visit (30+ min) | 142 | $3,006 |
| Lactate dehydrogenase (LD), (LDH) | 418 | $1,564 |
| Infusion, normal saline solution, 250 cc | 203 | $692 |
| Short return visit (20+ min) | 15 | $328 |
| Measurement of ferritin | 27 | $277 |
| Unclassified drugs | 67 | $277 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 60 | $170 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 12 | $106 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 24 | $0 |
2020
| Return visit (30+ min) | 243 | $5,222 |
| COMPREHENSIVE METABOLIC PANEL | 154 | $1,998 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 162 | $1,559 |
| Long return visit (40+ min) | 17 | $552 |
| Infusion, normal saline solution, 250 cc | 117 | $155 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 60 | $132 |
2019
| Return visit (30+ min) | 272 | $7,328 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 22 | $577 |
2018
| Return visit (30+ min) | 554 | $6,253 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 29 | $453 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 12 | $346 |
| Long return visit (40+ min) | 23 | $163 |
| Short return visit (20+ min) | 41 | $129 |
| Hospital outpatient clinic visit for assessment and management of a patient | 41 | $0 |
Drugs they prescribed that Part D paid
$10,049,505
Pharmacies billed $10,049,505 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (64 of 3,088) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%. Long-acting opioids: 19% of their opioid prescriptions.
2,191 generic and 897 brand-name prescriptions · $10,049,505 in drug cost · 299 antibiotic prescriptions to 106 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Revlimid | 88 | $1,385,389 | $15,743 |
| Jakafi | 69 | $1,129,872 | $16,375 |
| Pomalyst | 49 | $1,061,687 | $21,667 |
| Lenalidomide | 85 | $1,032,141 | $12,143 |
| Iclusig | 24 | $515,886 | $21,495 |
See all 64 drugs
| Revlimid | 88 | $1,385,389 | $15,743 |
| Jakafi | 69 | $1,129,872 | $16,375 |
| Pomalyst | 49 | $1,061,687 | $21,667 |
| Lenalidomide | 85 | $1,032,141 | $12,143 |
| Iclusig | 24 | $515,886 | $21,495 |
| Imbruvica | 30 | $496,722 | $16,557 |
| Sprycel | 48 | $493,257 | $10,276 |
| Promacta | 19 | $442,272 | $23,277 |
| Ayvakit | 12 | $440,053 | $36,671 |
| Brukinsa | 27 | $367,036 | $13,594 |
| Mekinist | 17 | $255,862 | $15,051 |
| Tagrisso | 12 | $204,556 | $17,046 |
| Tafinlar | 17 | $201,304 | $11,841 |
| Calquence | 12 | $176,639 | $14,720 |
| Dasatinib | 16 | $125,169 | $7,823 |
| Zarxio | 34 | $87,282 | $2,567 |
| Eliquis | 114 | $83,959 | $736 |
| Nubeqa | 11 | $69,580 | $6,325 |
| Venclexta | 42 | $68,864 | $1,640 |
| Cresemba | 12 | $65,114 | $5,426 |
| Imatinib Mesylate | 27 | $51,925 | $1,923 |
| Xarelto | 43 | $37,297 | $867 |
| Everolimus | 12 | $26,250 | $2,188 |
| Atovaquone | 47 | $15,426 | $328 |
| Enoxaparin | 25 | $8,642 | $346 |
| Acyclovir | 300 | $6,028 | $20 |
| Vascepa | 11 | $4,021 | $366 |
| Potassium Chloride | 69 | $3,260 | $47 |
| Hydroxyurea | 53 | $1,487 | $28 |
| Gabapentin | 49 | $1,011 | $21 |
| Fluconazole | 22 | $907 | $41 |
| Celecoxib | 28 | $890 | $32 |
| Hydrocodone-Acetaminophen | 35 | $872 | $25 |
| Ondansetron Odt | 52 | $807 | $16 |
| Allopurinol | 107 | $777 | $7 |
| Dexamethasone | 83 | $771 | $9 |
| Tamoxifen Citrate | 25 | $561 | $22 |
| Exemestane | 16 | $542 | $34 |
| Pantoprazole | 71 | $496 | $7 |
| Prochlorperazine Maleate | 58 | $484 | $8 |
| Sodium Chloride | 23 | $461 | $20 |
| Albuterol Sulfate Hfa | 12 | $455 | $38 |
| Anastrozole | 14 | $426 | $30 |
| Famotidine | 31 | $385 | $12 |
| Sulfamethoxazole-Trimethoprim | 186 | $369 | $2 |
| Valacyclovir | 15 | $298 | $20 |
| Prednisone | 86 | $282 | $3 |
| Hydrocortisone | 12 | $251 | $21 |
| Ondansetron | 44 | $228 | $5 |
| Montelukast | 57 | $218 | $4 |
| Levofloxacin | 36 | $216 | $6 |
| Lidocaine-Prilocaine | 17 | $196 | $12 |
| Levothyroxine | 25 | $173 | $7 |
| Lansoprazole | 17 | $160 | $9 |
| Loperamide | 13 | $129 | $10 |
| Omeprazole | 25 | $129 | $5 |
| Clopidogrel | 11 | $109 | $10 |
| Azithromycin | 25 | $106 | $4 |
| Furosemide | 36 | $99 | $3 |
| Venlafaxine Hcl Er | 15 | $92 | $6 |
| Triamcinolone Acetonide | 14 | $86 | $6 |
| Lorazepam | 14 | $82 | $6 |
| Metoclopramide | 16 | $76 | $5 |
| Trazodone | 16 | $44 | $3 |
Year by year
| 2024 | 3,088 | 297 | 2% (64) | 29% | $10,049,505 |
| 2023 | 2,962 | 285 | 2% (52) | None | $7,917,232 |
| 2022 | 3,085 | 271 | 3% (105) | None | $9,406,489 |
| 2021 | 2,680 | 235 | 9% (229) | None | $7,856,729 |
| 2020 | 2,168 | 214 | 2% (47) | None | $7,626,146 |
| 2019 | 1,536 | 192 | 3% (39) | 35% | $5,654,556 |
| 2018 | 1,400 | 155 | 10% (133) | None | $4,057,519 |
| 2017 | 2,256 | 185 | 15% (329) | None | $3,989,537 |
| 2016 | 1,614 | 161 | 16% (251) | 20% | $1,862,059 |
| 2015 | 1,362 | 146 | 16% (223) | None | $888,971 |
| 2014 | 1,261 | 147 | 13% (169) | None | $665,305 |
| 2013 | 1,096 | 127 | 16% (179) | None | $388,582 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 63 drugs
| Revlimid | 58 | $1,074,023 | $18,518 |
| Lenalidomide | 74 | $1,031,241 | $13,936 |
| Jakafi | 45 | $758,875 | $16,864 |
| Pomalyst | 35 | $736,384 | $21,040 |
| Iclusig | 22 | $453,810 | $20,628 |
| Xpovio | 14 | $421,907 | $30,136 |
| Sprycel | 39 | $386,607 | $9,913 |
| Imbruvica | 18 | $281,169 | $15,620 |
| Calquence | 20 | $269,470 | $13,473 |
| Ibrance | 15 | $216,536 | $14,436 |
| Venclexta | 77 | $208,412 | $2,707 |
| Promacta | 11 | $208,399 | $18,945 |
| Tagrisso | 12 | $195,183 | $16,265 |
| Mekinist | 13 | $192,484 | $14,806 |
| Tafinlar | 14 | $168,522 | $12,037 |
| Ninlaro | 11 | $154,442 | $14,040 |
| Brukinsa | 11 | $148,632 | $13,512 |
| Everolimus | 12 | $64,606 | $5,384 |
| Eliquis | 85 | $63,527 | $747 |
| Zarxio | 28 | $56,133 | $2,005 |
| Xarelto | 63 | $56,067 | $890 |
| Posaconazole | 21 | $47,890 | $2,280 |
| Vemlidy | 17 | $25,237 | $1,485 |
| Sancuso | 11 | $18,823 | $1,711 |
| Atovaquone | 24 | $13,687 | $570 |
| Acyclovir | 321 | $8,893 | $28 |
| Enoxaparin | 11 | $7,918 | $720 |
| Exemestane | 29 | $6,009 | $207 |
| Potassium Chloride | 81 | $5,011 | $62 |
| Vascepa | 12 | $4,800 | $400 |
| Celecoxib | 33 | $2,079 | $63 |
| Hydroxyurea | 46 | $1,324 | $29 |
| Allopurinol | 140 | $1,194 | $9 |
| Gabapentin | 48 | $923 | $19 |
| Sulfamethoxazole-Trimethoprim | 163 | $903 | $6 |
| Albuterol Sulfate Hfa | 18 | $875 | $49 |
| Anastrozole | 28 | $844 | $30 |
| Ondansetron Odt | 54 | $838 | $16 |
| Prochlorperazine Maleate | 81 | $825 | $10 |
| Pantoprazole | 63 | $756 | $12 |
| Levofloxacin | 56 | $673 | $12 |
| Ondansetron | 57 | $575 | $10 |
| Prednisone | 117 | $501 | $4 |
| Dexamethasone | 69 | $487 | $7 |
| Entecavir | 19 | $444 | $23 |
| Mirtazapine | 19 | $430 | $23 |
| Tamoxifen Citrate | 11 | $411 | $37 |
| Fluconazole | 12 | $401 | $33 |
| Hydrocodone-Acetaminophen | 26 | $368 | $14 |
| Montelukast | 48 | $359 | $7 |
| Lidocaine-Prilocaine | 15 | $275 | $18 |
| Amoxicillin-Clavulanate Potass | 29 | $253 | $9 |
| Esomeprazole Magnesium | 11 | $244 | $22 |
| Famotidine | 25 | $242 | $10 |
| Triamcinolone Acetonide | 25 | $210 | $8 |
| Omeprazole | 30 | $209 | $7 |
| Levothyroxine | 19 | $182 | $10 |
| Furosemide | 31 | $132 | $4 |
| Methotrexate | 12 | $116 | $10 |
| Azithromycin | 21 | $110 | $5 |
| Amlodipine Besylate | 13 | $104 | $8 |
| Ibuprofen | 12 | $88 | $7 |
| Lorazepam | 13 | $21 | $2 |
2022: 61 drugs
| Revlimid | 146 | $2,791,664 | $19,121 |
| Pomalyst | 45 | $954,261 | $21,206 |
| Jakafi | 52 | $785,007 | $15,096 |
| Imbruvica | 41 | $634,015 | $15,464 |
| Sprycel | 44 | $468,025 | $10,637 |
| Ibrance | 28 | $424,074 | $15,145 |
| Ninlaro | 31 | $386,410 | $12,465 |
| Xpovio | 11 | $280,279 | $25,480 |
| Calquence | 18 | $263,803 | $14,656 |
| Tagrisso | 12 | $188,119 | $15,677 |
| Venclexta | 25 | $179,971 | $7,199 |
| Lynparza | 11 | $167,968 | $15,270 |
| Mekinist | 12 | $159,514 | $13,293 |
| Lenalidomide | 11 | $129,412 | $11,765 |
| Tafinlar | 12 | $129,336 | $10,778 |
| Inqovi | 15 | $104,849 | $6,990 |
| Eliquis | 128 | $77,537 | $606 |
| Xarelto | 37 | $35,844 | $969 |
| Posaconazole | 12 | $25,100 | $2,092 |
| Atovaquone | 21 | $17,546 | $836 |
| Acyclovir | 335 | $6,358 | $19 |
| Exemestane | 27 | $5,128 | $190 |
| Potassium Chloride | 74 | $1,839 | $25 |
| Ondansetron Odt | 79 | $1,554 | $20 |
| Entecavir | 13 | $1,493 | $115 |
| Ondansetron | 69 | $1,446 | $21 |
| Prochlorperazine Maleate | 89 | $1,208 | $14 |
| Hydrocodone-Acetaminophen | 55 | $1,199 | $22 |
| Allopurinol | 154 | $1,166 | $8 |
| Hydroxyurea | 56 | $1,164 | $21 |
| Dexamethasone | 83 | $958 | $12 |
| Anastrozole | 39 | $847 | $22 |
| Tacrolimus | 11 | $804 | $73 |
| Morphine Sulfate Er | 19 | $795 | $42 |
| Sulfamethoxazole-Trimethoprim | 179 | $651 | $4 |
| Gabapentin | 29 | $611 | $21 |
| Prednisone | 129 | $583 | $5 |
| Celecoxib | 19 | $556 | $29 |
| Letrozole | 12 | $522 | $44 |
| Azithromycin | 25 | $455 | $18 |
| Azathioprine | 15 | $435 | $29 |
| Mirtazapine | 11 | $405 | $37 |
| Pantoprazole | 40 | $397 | $10 |
| Omeprazole | 40 | $346 | $9 |
| Venlafaxine Hcl Er | 16 | $327 | $20 |
| Oxycodone | 13 | $323 | $25 |
| Fluconazole | 16 | $310 | $19 |
| Levetiracetam | 13 | $307 | $24 |
| Levothyroxine | 17 | $307 | $18 |
| Levofloxacin | 42 | $257 | $6 |
| Amoxicillin-Clavulanate Potass | 20 | $255 | $13 |
| Lidocaine-Prilocaine | 14 | $252 | $18 |
| Montelukast | 18 | $230 | $13 |
| Triamcinolone Acetonide | 33 | $214 | $6 |
| Furosemide | 44 | $191 | $4 |
| Ibuprofen | 31 | $187 | $6 |
| Famotidine | 25 | $179 | $7 |
| Amlodipine Besylate | 13 | $80 | $6 |
| Lorazepam | 14 | $74 | $5 |
| Alendronate | 16 | $67 | $4 |
| Penicillin V | 12 | $57 | $5 |
2021: 60 drugs
| Revlimid | 134 | $2,283,325 | $17,040 |
| Pomalyst | 39 | $788,038 | $20,206 |
| Imbruvica | 52 | $771,773 | $14,842 |
| Jakafi | 34 | $556,105 | $16,356 |
| Calquence | 32 | $475,538 | $14,861 |
| Ibrance | 33 | $443,047 | $13,426 |
| Ninlaro | 30 | $351,467 | $11,716 |
| Sprycel | 18 | $219,268 | $12,182 |
| Tagrisso | 12 | $183,980 | $15,332 |
| Lynparza | 12 | $177,901 | $14,825 |
| Erleada | 12 | $168,912 | $14,076 |
| Verzenio | 12 | $151,043 | $12,587 |
| Venclexta | 25 | $136,028 | $5,441 |
| Mekinist | 11 | $134,521 | $12,229 |
| Tafinlar | 11 | $109,071 | $9,916 |
| Promacta | 11 | $85,369 | $7,761 |
| Eliquis | 105 | $66,303 | $631 |
| Deferasirox | 11 | $44,281 | $4,026 |
| Posaconazole | 11 | $34,937 | $3,176 |
| Xarelto | 38 | $27,974 | $736 |
| Atovaquone | 22 | $16,692 | $759 |
| Oxycontin | 21 | $9,525 | $454 |
| Hydrocodone-Acetaminophen | 137 | $6,082 | $44 |
| Danazol | 21 | $5,483 | $261 |
| Acyclovir | 279 | $5,246 | $19 |
| Hydroxyurea | 69 | $2,184 | $32 |
| Dexamethasone | 96 | $1,613 | $17 |
| Exemestane | 17 | $1,345 | $79 |
| Valacyclovir | 11 | $1,250 | $114 |
| Allopurinol | 117 | $1,228 | $10 |
| Ondansetron Odt | 56 | $1,166 | $21 |
| Potassium Chloride | 61 | $1,163 | $19 |
| Morphine Sulfate Er | 38 | $1,089 | $29 |
| Azathioprine | 28 | $953 | $34 |
| Megestrol Acetate | 20 | $946 | $47 |
| Fluconazole | 27 | $784 | $29 |
| Anastrozole | 25 | $687 | $27 |
| Sulfamethoxazole-Trimethoprim | 147 | $597 | $4 |
| Letrozole | 33 | $565 | $17 |
| Ondansetron | 35 | $528 | $15 |
| Prochlorperazine Maleate | 47 | $473 | $10 |
| Prednisone | 86 | $460 | $5 |
| Levofloxacin | 42 | $443 | $11 |
| Montelukast | 15 | $430 | $29 |
| Tamoxifen Citrate | 11 | $422 | $38 |
| Oxycodone-Acetaminophen | 11 | $310 | $28 |
| Omeprazole | 32 | $285 | $9 |
| Levothyroxine | 13 | $284 | $22 |
| Pantoprazole | 17 | $244 | $14 |
| Azithromycin | 25 | $201 | $8 |
| Trazodone | 13 | $183 | $14 |
| Triamcinolone Acetonide | 21 | $179 | $9 |
| Famotidine | 15 | $143 | $10 |
| Amoxicillin-Clavulanate Potass | 14 | $124 | $9 |
| Furosemide | 32 | $120 | $4 |
| Alendronate | 29 | $106 | $4 |
| Gabapentin | 13 | $93 | $7 |
| Amlodipine Besylate | 13 | $81 | $6 |
| Lorazepam | 20 | $65 | $3 |
| Ibuprofen | 11 | $49 | $4 |
2020: 50 drugs
| Revlimid | 113 | $1,863,938 | $16,495 |
| Pomalyst | 46 | $866,629 | $18,840 |
| Imbruvica | 60 | $781,999 | $13,033 |
| Iclusig | 16 | $517,948 | $32,372 |
| Venclexta | 54 | $504,898 | $9,350 |
| Ibrance | 35 | $441,222 | $12,606 |
| Jakafi | 28 | $426,402 | $15,229 |
| Sprycel | 30 | $330,357 | $11,012 |
| Ninlaro | 25 | $266,051 | $10,642 |
| Calquence | 18 | $260,366 | $14,465 |
| Tagrisso | 16 | $245,391 | $15,337 |
| Promacta | 22 | $216,714 | $9,851 |
| Lynparza | 11 | $161,622 | $14,693 |
| Erleada | 11 | $145,821 | $13,256 |
| Mekinist | 11 | $120,504 | $10,955 |
| Tafinlar | 11 | $99,374 | $9,034 |
| Posaconazole | 12 | $49,218 | $4,102 |
| Eliquis | 67 | $42,458 | $634 |
| Xarelto | 37 | $29,820 | $806 |
| Acyclovir | 208 | $2,987 | $14 |
| Hydroxyurea | 46 | $2,208 | $48 |
| Dexamethasone | 90 | $1,666 | $19 |
| Allopurinol | 108 | $1,306 | $12 |
| Potassium Chloride | 30 | $1,176 | $39 |
| Letrozole | 43 | $1,071 | $25 |
| Azathioprine | 31 | $1,031 | $33 |
| Ondansetron Odt | 45 | $1,018 | $23 |
| Tamoxifen Citrate | 26 | $835 | $32 |
| Levofloxacin | 66 | $785 | $12 |
| Ondansetron | 42 | $720 | $17 |
| Hydrocodone-Acetaminophen | 22 | $644 | $29 |
| Fluconazole | 26 | $606 | $23 |
| Prochlorperazine Maleate | 52 | $574 | $11 |
| Megestrol Acetate | 11 | $491 | $45 |
| Sulfamethoxazole-Trimethoprim | 107 | $446 | $4 |
| Prednisone | 65 | $436 | $7 |
| Levothyroxine | 23 | $402 | $17 |
| Tacrolimus | 17 | $297 | $17 |
| Omeprazole | 19 | $269 | $14 |
| Gabapentin | 21 | $213 | $10 |
| Montelukast | 18 | $143 | $8 |
| Triamcinolone Acetonide | 19 | $117 | $6 |
| Amoxicillin-Clavulanate Potass | 12 | $116 | $10 |
| Tamsulosin | 12 | $102 | $9 |
| Pantoprazole | 14 | $99 | $7 |
| Alendronate | 18 | $97 | $5 |
| Azithromycin | 16 | $96 | $6 |
| Metoclopramide | 11 | $83 | $8 |
| Furosemide | 13 | $39 | $3 |
| Amlodipine Besylate | 11 | $36 | $3 |
2019: 39 drugs
| Revlimid | 102 | $1,590,879 | $15,597 |
| Pomalyst | 39 | $694,668 | $17,812 |
| Imbruvica | 50 | $590,220 | $11,804 |
| Jakafi | 20 | $424,376 | $21,219 |
| Sprycel | 33 | $383,810 | $11,631 |
| Ibrance | 26 | $307,755 | $11,837 |
| Tagrisso | 12 | $196,757 | $16,396 |
| Ninlaro | 15 | $160,728 | $10,715 |
| Zytiga | 11 | $122,258 | $11,114 |
| Mekinist | 11 | $114,802 | $10,437 |
| Tafinlar | 11 | $97,273 | $8,843 |
| Imatinib Mesylate | 11 | $68,396 | $6,218 |
| Eliquis | 40 | $22,611 | $565 |
| Xarelto | 29 | $18,279 | $630 |
| Potassium Chloride | 29 | $2,380 | $82 |
| Hydroxyurea | 20 | $1,750 | $88 |
| Acyclovir | 115 | $1,732 | $15 |
| Dexamethasone | 46 | $1,106 | $24 |
| Allopurinol | 69 | $855 | $12 |
| Tamoxifen Citrate | 11 | $784 | $71 |
| Ondansetron | 68 | $750 | $11 |
| Anastrozole | 17 | $692 | $41 |
| Hydrocodone-Acetaminophen | 14 | $471 | $34 |
| Fluconazole | 20 | $419 | $21 |
| Prochlorperazine Maleate | 50 | $404 | $8 |
| Prednisone | 69 | $390 | $6 |
| Ondansetron Odt | 19 | $358 | $19 |
| Sulfamethoxazole-Trimethoprim | 74 | $313 | $4 |
| Levothyroxine | 15 | $253 | $17 |
| Levofloxacin | 31 | $243 | $8 |
| Letrozole | 17 | $228 | $13 |
| Pantoprazole | 13 | $112 | $9 |
| Azithromycin | 19 | $110 | $6 |
| Metoclopramide | 15 | $107 | $7 |
| Furosemide | 29 | $90 | $3 |
| Gabapentin | 13 | $86 | $7 |
| Alendronate | 14 | $75 | $5 |
| Omeprazole | 14 | $72 | $5 |
| Amlodipine Besylate | 16 | $36 | $2 |
2018: 34 drugs
| Revlimid | 126 | $1,877,351 | $14,900 |
| Pomalyst | 32 | $538,234 | $16,820 |
| Tagrisso | 18 | $284,583 | $15,810 |
| Imbruvica | 23 | $265,030 | $11,523 |
| Ibrance | 19 | $217,027 | $11,422 |
| Jakafi | 14 | $186,921 | $13,352 |
| Promacta | 13 | $86,122 | $6,625 |
| Eliquis | 34 | $16,941 | $498 |
| Xarelto | 28 | $12,813 | $458 |
| Hydrocodone-Acetaminophen | 45 | $1,788 | $40 |
| Hydroxyurea | 23 | $1,705 | $74 |
| Morphine Sulfate Er | 25 | $995 | $40 |
| Tamoxifen Citrate | 25 | $988 | $40 |
| Acyclovir | 80 | $986 | $12 |
| Anastrozole | 32 | $782 | $24 |
| Oxycodone-Acetaminophen | 21 | $722 | $34 |
| Dexamethasone | 43 | $552 | $13 |
| Ondansetron | 66 | $523 | $8 |
| Allopurinol | 28 | $368 | $13 |
| Prednisone | 55 | $342 | $6 |
| Levofloxacin | 19 | $244 | $13 |
| Tacrolimus | 11 | $238 | $22 |
| Sulfamethoxazole-Trimethoprim | 62 | $231 | $4 |
| Prochlorperazine Maleate | 35 | $213 | $6 |
| Gabapentin | 13 | $198 | $15 |
| Warfarin | 18 | $187 | $10 |
| Potassium Chloride | 11 | $186 | $17 |
| Letrozole | 12 | $182 | $15 |
| Azithromycin | 21 | $154 | $7 |
| Omeprazole | 24 | $142 | $6 |
| Triamcinolone Acetonide | 12 | $97 | $8 |
| Zolpidem | 15 | $95 | $6 |
| Amlodipine Besylate | 13 | $62 | $5 |
| Furosemide | 16 | $39 | $2 |
2017: 59 drugs
| Revlimid | 132 | $1,775,255 | $13,449 |
| Pomalyst | 27 | $402,449 | $14,906 |
| Tagrisso | 19 | $284,979 | $14,999 |
| Gleevec | 19 | $245,948 | $12,945 |
| Ibrance | 22 | $245,547 | $11,161 |
| Ninlaro | 19 | $183,256 | $9,645 |
| Imbruvica | 13 | $152,563 | $11,736 |
| Afinitor | 11 | $142,166 | $12,924 |
| Sprycel | 11 | $73,375 | $6,670 |
| Eliquis | 32 | $13,383 | $418 |
| Xarelto | 29 | $12,807 | $442 |
| Oxycontin | 28 | $11,959 | $427 |
| Enoxaparin | 14 | $6,824 | $487 |
| Exemestane | 15 | $4,315 | $288 |
| Hydrocodone-Acetaminophen | 114 | $3,518 | $31 |
| Morphine Sulfate Er | 65 | $2,673 | $41 |
| Potassium Chloride | 44 | $2,382 | $54 |
| Hydroxyurea | 23 | $1,687 | $73 |
| Acyclovir | 143 | $1,683 | $12 |
| Oxycodone-Acetaminophen | 47 | $1,481 | $32 |
| Duloxetine | 15 | $1,068 | $71 |
| Tamoxifen Citrate | 32 | $1,059 | $33 |
| Ondansetron | 87 | $855 | $10 |
| Fluconazole | 25 | $769 | $31 |
| Morphine Sulfate | 21 | $694 | $33 |
| Loperamide | 11 | $661 | $60 |
| Megestrol Acetate | 16 | $623 | $39 |
| Dexamethasone | 64 | $559 | $9 |
| Anastrozole | 17 | $520 | $31 |
| Oxycodone | 21 | $488 | $23 |
| Lidocaine-Prilocaine | 17 | $475 | $28 |
| Tacrolimus | 14 | $456 | $33 |
| Levetiracetam | 13 | $421 | $32 |
| Allopurinol | 46 | $419 | $9 |
| Prochlorperazine Maleate | 49 | $396 | $8 |
| Omeprazole | 43 | $368 | $9 |
| Azathioprine | 12 | $356 | $30 |
| Doxycycline Monohydrate | 15 | $330 | $22 |
| Prednisone | 60 | $328 | $5 |
| Sulfamethoxazole-Trimethoprim | 90 | $298 | $3 |
| Levofloxacin | 23 | $283 | $12 |
| Ondansetron Odt | 37 | $248 | $7 |
| Metronidazole | 14 | $243 | $17 |
| Lorazepam | 36 | $233 | $6 |
| Methadone | 13 | $219 | $17 |
| Azithromycin | 37 | $209 | $6 |
| Letrozole | 12 | $179 | $15 |
| Gabapentin | 27 | $178 | $7 |
| Zolpidem | 30 | $150 | $5 |
| Warfarin | 21 | $139 | $7 |
| Furosemide | 52 | $132 | $3 |
| Mirtazapine | 15 | $111 | $7 |
| Amlodipine Besylate | 24 | $88 | $4 |
| Escitalopram | 16 | $83 | $5 |
| Metoclopramide | 25 | $81 | $3 |
| Triamcinolone Acetonide | 11 | $68 | $6 |
| Ciprofloxacin | 12 | $67 | $6 |
| Spironolactone | 11 | $48 | $4 |
| Famotidine | 12 | $39 | $3 |
2016: 44 drugs
| Revlimid | 71 | $682,725 | $9,616 |
| Gleevec | 21 | $214,491 | $10,214 |
| Xarelto | 36 | $13,329 | $370 |
| Enoxaparin | 19 | $8,848 | $466 |
| Oxycontin | 21 | $8,049 | $383 |
| Morphine Sulfate Er | 58 | $3,244 | $56 |
| Hydrocodone-Acetaminophen | 70 | $2,671 | $38 |
| Hydroxyurea | 19 | $1,668 | $88 |
| Oxycodone-Acetaminophen | 35 | $1,401 | $40 |
| Acyclovir | 89 | $1,199 | $13 |
| Ondansetron | 60 | $859 | $14 |
| Morphine Sulfate | 15 | $550 | $37 |
| Dexamethasone | 67 | $450 | $7 |
| Levofloxacin | 30 | $449 | $15 |
| Anastrozole | 22 | $429 | $20 |
| Potassium Chloride | 24 | $424 | $18 |
| Tacrolimus | 19 | $418 | $22 |
| Doxycycline Monohydrate | 26 | $407 | $16 |
| Ondansetron Odt | 38 | $356 | $9 |
| Prochlorperazine Maleate | 46 | $309 | $7 |
| Oxycodone | 13 | $304 | $23 |
| Loperamide | 12 | $292 | $24 |
| Omeprazole | 32 | $288 | $9 |
| Prednisone | 37 | $213 | $6 |
| Letrozole | 15 | $207 | $14 |
| Allopurinol | 21 | $198 | $9 |
| Amlodipine Besylate | 31 | $186 | $6 |
| Gabapentin | 15 | $168 | $11 |
| Methadone | 13 | $167 | $13 |
| Azithromycin | 23 | $153 | $7 |
| Azathioprine | 12 | $150 | $13 |
| Furosemide | 46 | $134 | $3 |
| Sulfamethoxazole-Trimethoprim | 32 | $133 | $4 |
| Venlafaxine | 12 | $124 | $10 |
| Warfarin | 18 | $96 | $5 |
| Alendronate | 13 | $85 | $7 |
| Escitalopram | 17 | $82 | $5 |
| Triamcinolone Acetonide | 12 | $81 | $7 |
| Lorazepam | 21 | $81 | $4 |
| Spironolactone | 13 | $79 | $6 |
| Zolpidem | 18 | $66 | $4 |
| Famotidine | 12 | $54 | $4 |
| Ibuprofen | 12 | $46 | $4 |
| Tramadol | 15 | $44 | $3 |
2015: 41 drugs
| Revlimid | 31 | $238,018 | $7,678 |
| Gleevec | 17 | $160,771 | $9,457 |
| Tarceva | 13 | $87,532 | $6,733 |
| Xarelto | 42 | $16,734 | $398 |
| Creon | 12 | $7,259 | $605 |
| Oxycontin | 13 | $3,997 | $307 |
| Spiriva | 12 | $3,789 | $316 |
| Hydrocodone-Acetaminophen | 87 | $3,516 | $40 |
| Oxycodone-Acetaminophen | 23 | $2,149 | $93 |
| Morphine Sulfate Er | 33 | $1,539 | $47 |
| Anastrozole | 52 | $1,085 | $21 |
| Acyclovir | 73 | $993 | $14 |
| Hydroxyurea | 11 | $930 | $85 |
| Oxycodone | 15 | $892 | $59 |
| Ondansetron | 48 | $690 | $14 |
| Tamoxifen Citrate | 13 | $558 | $43 |
| Dexamethasone | 49 | $470 | $10 |
| Ondansetron Odt | 11 | $448 | $41 |
| Levofloxacin | 30 | $443 | $15 |
| Warfarin | 40 | $387 | $10 |
| Diphenoxylate-Atropine | 24 | $349 | $15 |
| Morphine Sulfate | 17 | $342 | $20 |
| Prochlorperazine Maleate | 41 | $327 | $8 |
| Polyethylene Glycol 3350 | 12 | $305 | $25 |
| Zolpidem | 23 | $269 | $12 |
| Gabapentin | 24 | $261 | $11 |
| Venlafaxine | 13 | $255 | $20 |
| Potassium Chloride | 24 | $238 | $10 |
| Omeprazole | 26 | $207 | $8 |
| Amlodipine Besylate | 17 | $196 | $12 |
| Allopurinol | 19 | $157 | $8 |
| Letrozole | 28 | $157 | $6 |
| Sulfamethoxazole-Trimethoprim | 46 | $156 | $3 |
| Azithromycin | 22 | $155 | $7 |
| Escitalopram | 14 | $124 | $9 |
| Methadone | 12 | $120 | $10 |
| Prednisone | 25 | $109 | $4 |
| Alendronate | 12 | $82 | $7 |
| Lorazepam | 25 | $80 | $3 |
| Tramadol | 13 | $66 | $5 |
| Furosemide | 21 | $53 | $3 |
2014: 37 drugs
| Revlimid | 26 | $206,060 | $7,925 |
| Tarceva | 17 | $97,405 | $5,730 |
| Enoxaparin | 18 | $24,013 | $1,334 |
| Xarelto | 36 | $13,498 | $375 |
| Oxycontin | 11 | $6,103 | $555 |
| Nexium | 17 | $4,534 | $267 |
| Spiriva | 11 | $3,200 | $291 |
| Ondansetron | 77 | $2,267 | $29 |
| Hydrocodone-Acetaminophen | 53 | $1,953 | $37 |
| Anastrozole | 56 | $1,847 | $33 |
| Vicodin | 13 | $1,405 | $108 |
| Morphine Sulfate Er | 21 | $1,377 | $66 |
| Oxycodone | 25 | $1,042 | $42 |
| Ondansetron Odt | 27 | $1,027 | $38 |
| Acyclovir | 51 | $901 | $18 |
| Megestrol Acetate | 23 | $851 | $37 |
| Dexamethasone | 78 | $717 | $9 |
| Tamoxifen Citrate | 16 | $611 | $38 |
| Prochlorperazine Maleate | 67 | $564 | $8 |
| Proair Hfa | 11 | $545 | $50 |
| Venlafaxine | 15 | $517 | $34 |
| Omeprazole | 42 | $436 | $10 |
| Levofloxacin | 24 | $381 | $16 |
| Morphine Sulfate | 14 | $300 | $21 |
| Polyethylene Glycol 3350 | 11 | $250 | $23 |
| Escitalopram | 11 | $191 | $17 |
| Warfarin | 22 | $162 | $7 |
| Pantoprazole | 20 | $153 | $8 |
| Prednisone | 25 | $150 | $6 |
| Sulfamethoxazole-Trimethoprim | 30 | $137 | $5 |
| Zolpidem | 19 | $123 | $6 |
| Gabapentin | 11 | $89 | $8 |
| Alprazolam | 11 | $85 | $8 |
| Lisinopril | 16 | $76 | $5 |
| Amlodipine Besylate | 12 | $58 | $5 |
| Furosemide | 20 | $58 | $3 |
| Tramadol | 12 | $54 | $4 |
2013: 31 drugs
| Revlimid | 12 | $103,469 | $8,622 |
| Tarceva | 13 | $71,769 | $5,521 |
| Enoxaparin | 19 | $45,640 | $2,402 |
| Oxycontin | 17 | $7,901 | $465 |
| Xarelto | 23 | $6,024 | $262 |
| Spiriva | 11 | $3,017 | $274 |
| Ondansetron | 68 | $2,222 | $33 |
| Megestrol Acetate | 21 | $1,310 | $62 |
| Morphine Sulfate Er | 23 | $1,111 | $48 |
| Anastrozole | 25 | $963 | $39 |
| Hydrocodone-Acetaminophen | 70 | $764 | $11 |
| Escitalopram | 12 | $743 | $62 |
| Acyclovir | 37 | $723 | $20 |
| Oxycodone | 25 | $695 | $28 |
| Omeprazole | 45 | $681 | $15 |
| Letrozole | 16 | $668 | $42 |
| Prochlorperazine Maleate | 60 | $589 | $10 |
| Polyethylene Glycol 3350 | 21 | $552 | $26 |
| Dexamethasone | 69 | $481 | $7 |
| Morphine Sulfate | 20 | $457 | $23 |
| Levofloxacin | 33 | $358 | $11 |
| Gabapentin | 19 | $328 | $17 |
| Tamoxifen Citrate | 11 | $258 | $23 |
| Zolpidem | 25 | $186 | $7 |
| Pantoprazole | 18 | $165 | $9 |
| Sulfamethoxazole-Trimethoprim | 19 | $117 | $6 |
| Prednisone | 16 | $106 | $7 |
| Alendronate | 11 | $99 | $9 |
| Furosemide | 20 | $63 | $3 |
| Allopurinol | 11 | $51 | $5 |
| Alprazolam | 12 | $51 | $4 |
Money from drug and device companies
$92,626 in 2025
| 2025 | 45 | 243 | $82,524 | $92,626 |
| 2024 | 34 | 171 | $51,269 | $75,595 |
| 2023 | 25 | 103 | $50,727 | $58,192 |
| 2022 | 24 | 71 | $32,706 | $35,971 |
| 2021 | 16 | 31 | $23,167 | $23,865 |
| 2020 | 12 | 34 | $16,864 | $17,283 |
| 2019 | 11 | 121 | $35,275 | $43,701 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genentech | Columvi | $40,148 | 5 payments
|
| Genentech USA | Lunsumio | $15,206 | 26 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $11,852 | 13 payments
|
| Incyte | Monjuvi | $7,964 | 7 payments
|
| Novartis Pharmaceuticals | Scemblix | $5,170 | 21 payments
|
| Abbvie | Venclexta | $4,761 | 17 payments
|
See all 228 published payments
| Sobi | Meals · 2025-12-26 | Vonjo | $15 |
| Sobi | Meals · 2025-12-24 | Vonjo | $28 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-23 | None | $16 |
| Daiichi Sankyo | Meals · 2025-12-22 | Vanflyta | $21 |
| Sobi | Meals · 2025-12-22 | Vonjo | $3 |
| GlaxoSmithKline | Meals · 2025-12-18 | Blenrep | $12 |
| GlaxoSmithKline | Meals · 2025-12-18 | Blenrep | $1 |
| PharmaEssentia USA | Meals · 2025-12-17 | Besremi | $23 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-12-16 | None | $2,050 |
| Nuvation Bio | Meals · 2025-12-16 | Ibtrozi | $24 |
| Novartis Pharmaceuticals | Meals · 2025-12-10 | Fabhalta | $25 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-08 | Opdivo | $21 |
| Amgen | Meals · 2025-12-07 | None | $50 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-06 | None | $60 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-06 | Calquence | $124 |
| F. Hoffmann-La Roche AG | Consulting · 2025-12-05 | None | $1,900 |
| F. Hoffmann-La Roche AG | Meals · 2025-12-05 | None | $28 |
| Genentech USA | Meals · 2025-12-05 | None | $221 |
| Genentech USA | Consulting · 2025-12-05 | None | $1,882 |
| Genentech USA | Meals · 2025-12-04 | Polivy | $19 |
| Astellas Pharma US | Meals · 2025-12-04 | Cresemba | $25 |
| Abbvie | Meals · 2025-12-02 | Venclexta | $18 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-01 | None | $21 |
| Genentech USA | Meals · 2025-12-01 | Polivy | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-26 | None | $15 |
| Sobi | Meals · 2025-11-25 | Vonjo | $4 |
| Genzyme | Meals · 2025-11-24 | Sarclisa | $23 |
| GlaxoSmithKline | Meals · 2025-11-22 | Blenrep | $15 |
| GlaxoSmithKline | Meals · 2025-11-21 | Blenrep | $1 |
| Pfizer | Meals · 2025-11-21 | Elrexfio | $11 |
| Janssen Biotech | Meals · 2025-11-19 | Rybrevant | $22 |
| Daiichi Sankyo | Meals · 2025-11-13 | Vanflyta | $12 |
| Abbvie | Travel · 2025-11-11 | None | $260 |
| Abbvie | Consulting · 2025-11-11 | None | $3,375 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-10 | Calquence | $26 |
| Stemline Therapeutics | Meals · 2025-11-08 | Orserdu | $31 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-05 | None | $8 |
| Novartis Pharmaceuticals | Meals · 2025-11-04 | Scemblix | $23 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-03 | Opdivo | $21 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-30 | Iclusig | $20 |
| Jazz Pharmaceuticals | Meals · 2025-10-30 | Zepzelca | $18 |
| Abbvie | Meals · 2025-10-25 | Epkinly | $25 |
| Abbvie | Meals · 2025-10-25 | Epkinly | $70 |
| Abbvie | Meals · 2025-10-25 | Epkinly | $60 |
| GlaxoSmithKline | Meals · 2025-10-24 | Ojjaara | $20 |
| Abbvie | Travel · 2025-10-24 | Epkinly | $172 |
| Jazz Pharmaceuticals | Meals · 2025-10-22 | Zepzelca | $18 |
| Novartis Pharmaceuticals | Meals · 2025-10-10 | Pluvicto | $10 |
| Array Biopharma | Meals · 2025-10-09 | Lorbrena | $21 |
| Sobi | Meals · 2025-10-09 | Vonjo | $28 |
| Genentech USA | Meals · 2025-10-08 | Polivy | $21 |
| Astellas Pharma US | Meals · 2025-09-25 | Cresemba | $16 |
| Cumberland Pharmaceuticals | Meals · 2025-09-25 | Sancuso | $16 |
| Pfizer | Meals · 2025-09-24 | Elrexfio | $17 |
| Pfizer | Meals · 2025-09-22 | Padcev | $24 |
| Incyte | Consulting · 2025-09-18 | Monjuvi | $6,165 |
| Kite Pharma | Meals · 2025-09-17 | Yescarta | $66 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-09-16 | None | $1,704 |
| Genzyme | Meals · 2025-09-15 | Ayvakit | $16 |
| Kite Pharma | Meals · 2025-09-12 | Yescarta | $21 |
| Kite Pharma | Meals · 2025-09-11 | Yescarta | $2 |
| Regeneron Healthcare Solutions | Meals · 2025-09-11 | Lynozyfic | $21 |
| PharmaEssentia USA | Meals · 2025-09-10 | Besremi | $25 |
| Kedrion Biopharma | Meals · 2025-09-05 | Albuked | $41 |
| Incyte | Travel · 2025-09-05 | Monjuvi | $259 |
| Adc Therapeutics America | Meals · 2025-09-05 | Zynlonta | $135 |
| GlaxoSmithKline | Meals · 2025-09-04 | Ojjaara | $14 |
| Incyte | Meals · 2025-09-04 | Monjuvi | $18 |
| Incyte | Meals · 2025-09-04 | Monjuvi | $107 |
| Incyte | Travel · 2025-09-04 | Monjuvi | $711 |
| Daiichi Sankyo | Meals · 2025-08-29 | Datroway | $23 |
| Abbvie | Meals · 2025-08-28 | Venclexta | $16 |
| Incyte | Consulting · 2025-08-28 | Monjuvi | $685 |
| Genentech USA | Meals · 2025-08-27 | Polivy | $21 |
| Daiichi Sankyo | Meals · 2025-08-22 | Enhertu | $11 |
| BeOne Medicines USA | Meals · 2025-08-22 | Brukinsa | $14 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-08-21 | Kisqali | $100 |
| Genentech USA | Consulting · 2025-08-21 | Lunsumio | $4,209 |
| Genentech USA | Meals · 2025-08-21 | Lunsumio | $40 |
| Genentech USA | Meals · 2025-08-21 | Lunsumio | $26 |
| Genentech USA | Meals · 2025-08-21 | Lunsumio | $50 |
| Genentech USA | Meals · 2025-08-20 | Lunsumio | $22 |
| Genentech USA | Travel · 2025-08-20 | Lunsumio | $474 |
| Genentech USA | Travel · 2025-08-20 | Lunsumio | $608 |
| Genentech USA | Meals · 2025-08-20 | Lunsumio | $38 |
| Genentech USA | Meals · 2025-08-20 | Lunsumio | $32 |
| Genentech USA | Consulting · 2025-08-20 | Lunsumio | $5,207 |
| Genentech USA | Travel · 2025-08-20 | Lunsumio | $86 |
| Genentech USA | Meals · 2025-08-20 | Lunsumio | $210 |
| Astellas Pharma US | Education · 2025-08-19 | None | $93 |
| Daiichi Sankyo | Meals · 2025-08-18 | Enhertu | $30 |
| Abbvie | Meals · 2025-08-14 | Elahere | $25 |
| Abbvie | Meals · 2025-08-14 | Elahere | $0 |
| Abbvie | Meals · 2025-08-14 | Elahere | $1 |
| Astellas Pharma US | Meals · 2025-08-13 | Xospata | $84 |
| Novartis Pharmaceuticals | Meals · 2025-08-12 | Fabhalta | $25 |
| Syndax Pharmaceuticals | Meals · 2025-08-12 | None | $16 |
| Merck Sharp & Dohme | Meals · 2025-08-11 | Keytruda | $18 |
| Sobi | Meals · 2025-08-11 | Vonjo | $5 |
| Array Biopharma | Meals · 2025-08-06 | Xalkori | $16 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-31 | Calquence | $21 |
| Celgene | Meals · 2025-07-30 | Opdivo | $22 |
| Abbvie | Consulting · 2025-07-30 | Venclexta | $675 |
| Sobi | Meals · 2025-07-30 | Vonjo | $14 |
| Sobi | Meals · 2025-07-30 | Vonjo | $1 |
| Sobi | Meals · 2025-07-30 | Vonjo | $2 |
| GlaxoSmithKline | Meals · 2025-07-29 | Ojjaara | $12 |
| Celgene | Meals · 2025-07-25 | None | $26 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-07-25 | Kisqali | $100 |
| Novartis Pharmaceuticals | Meals · 2025-07-25 | Scemblix | $15 |
| Astellas Pharma US | Meals · 2025-07-24 | Cresemba | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-23 | Tagrisso | $21 |
| Genzyme | Meals · 2025-07-17 | None | $122 |
| Genentech USA | Meals · 2025-07-16 | Polivy | $29 |
| Novartis Pharmaceuticals | Consulting · 2025-07-15 | Scemblix | $1,400 |
| Eisai | Meals · 2025-07-15 | Lenvima | $25 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-12 | None | $65 |
| Pfizer | Meals · 2025-07-09 | Elrexfio | $18 |
| Exelixis | Meals · 2025-07-07 | Cabometyx | $28 |
| Abbvie | Meals · 2025-07-02 | Elahere | $15 |
| Genentech | Consulting · 2025-07-02 | Columvi | $18,275 |
| Genentech | Meals · 2025-07-02 | Columvi | $42 |
| Genentech | Consulting · 2025-07-02 | Columvi | $20,400 |
| Array Biopharma | Meals · 2025-06-27 | Xalkori | $20 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-06-26 | None | $2,485 |
| Novartis Pharmaceuticals | Meals · 2025-06-26 | Kisqali | $25 |
| Jazz Pharmaceuticals | Meals · 2025-06-26 | Rylaze | $17 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-06-25 | None | $5,680 |
| Array Biopharma | Meals · 2025-06-24 | Braftovi | $3 |
| Alexion Pharmaceuticals | Meals · 2025-06-23 | Ultomiris | $25 |
| Array Biopharma | Meals · 2025-06-23 | Braftovi | $9 |
| Abbvie | Meals · 2025-06-21 | Epkinly | $7 |
| Abbvie | Meals · 2025-06-19 | Epkinly | $16 |
| Abbvie | Meals · 2025-06-19 | Epkinly | $2 |
| Genentech USA | Meals · 2025-06-13 | Venclexta | $24 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-06-12 | Kisqali | $100 |
| EMD Serono | Meals · 2025-06-11 | None | $19 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-10 | Enhertu | $26 |
| Sumitomo Pharma America | Meals · 2025-06-09 | Orgovyx | $20 |
| Sumitomo Pharma America | Meals · 2025-06-09 | Orgovyx | $19 |
| GlaxoSmithKline | Meals · 2025-06-06 | Ojjaara | $1 |
| Sobi | Meals · 2025-06-06 | Doptelet | $16 |
| GlaxoSmithKline | Meals · 2025-06-04 | Ojjaara | $34 |
| Kite Pharma | Meals · 2025-06-04 | Yescarta | $10 |
| Daiichi Sankyo | Meals · 2025-06-03 | Vanflyta | $14 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-03 | Enhertu | $28 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-30 | None | $18 |
| Eisai | Meals · 2025-05-29 | Lenvima | $34 |
| Pfizer | Meals · 2025-05-23 | Elrexfio | $16 |
| Astellas Pharma US | Education · 2025-05-23 | None | $75 |
| Novartis Pharmaceuticals | Meals · 2025-05-22 | Scemblix | $22 |
| Sobi | Meals · 2025-05-21 | Vonjo | $34 |
| Abbvie | Meals · 2025-05-19 | Imbruvica | $24 |
| Janssen Biotech | Meals · 2025-05-16 | Rybrevant | $20 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-05-15 | Kisqali | $100 |
| Ipsen Biopharmaceuticals | Meals · 2025-05-15 | Onivyde | $30 |
| Astellas Pharma US | Education · 2025-05-09 | None | $75 |
| GlaxoSmithKline | Meals · 2025-05-08 | Ojjaara | $26 |
| Genentech | Travel · 2025-05-08 | Columvi | $550 |
| Array Biopharma | Meals · 2025-05-07 | Lorbrena | $11 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-06 | None | $32 |
| Pfizer | Meals · 2025-05-01 | Padcev | $22 |
| Astellas Pharma US | Meals · 2025-04-30 | Cresemba | $22 |
| Janssen Biotech | Meals · 2025-04-28 | Carvykti | $14 |
| Novartis Pharmaceuticals | Meals · 2025-04-25 | Kisqali | $22 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-04-24 | Kisqali | $100 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-24 | Calquence | $24 |
| Genentech | Travel · 2025-04-24 | Columvi | $880 |
| Seagen | Education · 2025-04-24 | None | $89 |
| Adc Therapeutics America | Meals · 2025-04-24 | Zynlonta | $6 |
| Biocon Biologics | Meals · 2025-04-24 | Ogivri | $28 |
| Janssen Biotech | Meals · 2025-04-22 | Talvey | $15 |
| BeOne Medicines USA | Meals · 2025-04-22 | Tevimbra | $26 |
| Genentech USA | Meals · 2025-04-18 | Polivy | $21 |
| PharmaEssentia USA | Meals · 2025-04-18 | Besremi | $18 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-16 | Tagrisso | $31 |
| Genentech USA | Consulting · 2025-04-16 | Lunsumio | $1,882 |
| Sobi | Meals · 2025-04-10 | Vonjo | $21 |
| Novartis Pharmaceuticals | Meals · 2025-04-04 | Scemblix | $17 |
| Incyte | Meals · 2025-04-03 | Jakafi | $19 |
| Agios Pharmaceuticals | Meals · 2025-04-01 | Pyrukynd | $20 |
| Genentech USA | Meals · 2025-03-31 | Polivy | $19 |
| Sobi | Meals · 2025-03-30 | Vonjo | $8 |
| Sobi | Meals · 2025-03-30 | Vonjo | $0 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-03-26 | Kisqali | $100 |
| Janssen Biotech | Meals · 2025-03-24 | Erleada | $22 |
| Lilly USA | Meals · 2025-03-21 | Verzenio | $14 |
| Novartis Pharmaceuticals | Consulting · 2025-03-21 | None | $2,100 |
| Array Biopharma | Meals · 2025-03-21 | Braftovi | $3 |
| Genentech USA | Meals · 2025-03-17 | Polivy | $11 |
| Genentech USA | Meals · 2025-03-17 | Polivy | $1 |
| SpringWorks Therapeutics | Meals · 2025-03-14 | Ogsiveo | $16 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-07 | None | $16 |
| Daiichi Sankyo | Meals · 2025-03-07 | Enhertu | $9 |
| Merck Sharp & Dohme | Meals · 2025-03-07 | None | $15 |
| Astellas Pharma US | Meals · 2025-03-06 | Xtandi | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-28 | Tagrisso | $23 |
| Celgene | Meals · 2025-02-21 | Opdivo | $19 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-02-21 | Kisqali | $100 |
| Celgene | Meals · 2025-02-20 | Reblozyl | $16 |
| Daiichi Sankyo | Meals · 2025-02-20 | Vanflyta | $14 |
| Novartis Pharmaceuticals | Meals · 2025-02-14 | Scemblix | $14 |
| Kite Pharma | Meals · 2025-02-14 | None | $116 |
| Pfizer | Meals · 2025-02-12 | Elrexfio | $16 |
| Exelixis | Meals · 2025-02-11 | Cabometyx | $22 |
| BeiGene USA | Meals · 2025-02-09 | Brukinsa | $16 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-07 | Enhertu | $77 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-06 | Tagrisso | $19 |
| Eisai | Meals · 2025-02-05 | Lenvima | $20 |
| Pfizer | Meals · 2025-01-30 | Ibrance | $3 |
| Pfizer | Meals · 2025-01-30 | Ibrance | $19 |
| Daiichi Sankyo | Meals · 2025-01-29 | Vanflyta | $21 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-01-28 | Alunbrig | $22 |
| Karyopharm Therapeutics | Meals · 2025-01-24 | Xpovio | $22 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-01-23 | Kisqali | $100 |
| Sobi | Meals · 2025-01-23 | Vonjo | $7 |
| TerSera Therapeutics | Meals · 2025-01-23 | Zoladex | $31 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-01-22 | None | $1,775 |
| Genentech USA | Meals · 2025-01-22 | Columvi | $23 |
| Merck Sharp & Dohme | Meals · 2025-01-21 | Keytruda | $28 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-17 | Opdualag | $21 |
| Sobi | Education · 2025-01-17 | None | $85 |
| Daiichi Sankyo | Meals · 2025-01-14 | Vanflyta | $21 |
| Pfizer | Meals · 2025-01-13 | Xtandi | $29 |
| GlaxoSmithKline | Meals · 2025-01-10 | Ojjaara | $1 |
| GlaxoSmithKline | Meals · 2025-01-09 | Ojjaara | $15 |
| Astellas Pharma US | Education · 2025-01-08 | None | $90 |
| Novartis Pharmaceuticals | Consulting · 2025-01-01 | Scemblix | $675 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $75,595
| F. Hoffmann-La Roche AG | Polivy | $23,344 | 13 payments
|
| Genentech USA | Polivy | $16,994 | 13 payments
|
| Abbvie | Venclexta | $10,067 | 17 payments
|
| AstraZeneca Pharmaceuticals LP | Calquence | $9,296 | 10 payments
|
| Novartis Pharmaceuticals | Scemblix | $5,513 | 22 payments
|
| Genmab U.S. | None | $4,180 | 6 payments
|
| E.R. Squibb & Sons L.L.C. | Opdualag | $3,061 | 11 payments
|
| Pfizer | Elrexfio | $1,184 | 6 payments
|
| Celgene | Reblozyl | $334 | 13 payments
|
| Alexion Pharmaceuticals | Ultomiris | $199 | 3 payments
|
| Genentech | None | $149 | 1 payment
|
| Janssen Biotech | Erleada | $139 | 9 payments
|
| GlaxoSmithKline | Jemperli | $134 | 8 payments
|
| Rigel Pharmaceuticals | Rezlidhia | $121 | 1 payment
|
| Astellas Pharma US | Xtandi | $102 | 2 payments
|
| Genzyme | Sarclisa | $95 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $81 | 4 payments
|
| Sobi | Vonjo | $76 | 4 payments
|
| Eisai | Lenvima | $73 | 3 payments
|
| Exelixis | Cabometyx | $64 | 2 payments
|
| SpringWorks Therapeutics | Ogsiveo | $59 | 3 payments
|
| Servier Pharmaceuticals | Tibsovo | $50 | 2 payments
|
| Ipsen Biopharmaceuticals | Onivyde | $48 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Iclusig | $37 | 2 payments
|
| Apellis Pharmaceuticals | Empaveli | $28 | 1 payment
|
| Taiho Oncology | Lonsurf | $25 | 1 payment
|
| Array Biopharma | Braftovi | $23 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $23 | 1 payment
|
| Incyte | Monjuvi | $20 | 1 payment
|
| Blueprint Medicines | Ayvakit | $19 | 1 payment
|
| PharmaEssentia USA | Besremi | $17 | 1 payment
|
| EMD Serono | None | $15 | 1 payment
|
| Daiichi Sankyo | Vanflyta | $14 | 1 payment
|
| Agios Pharmaceuticals | Pyrukynd | $13 | 1 payment
|
2023: $58,192
| Genentech USA | Polivy | $41,578 | 26 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $3,417 | 17 payments
|
| AbbVie | Epkinly | $3,050 | 5 payments
|
| AstraZeneca Pharmaceuticals LP | Calquence | $2,415 | 3 payments
|
| Janssen Scientific Affairs | Tecvayli | $2,168 | 3 payments
|
| Servier Pharmaceuticals | Tibsovo | $2,069 | 3 payments
|
| MorphoSys AG | Monjuvi | $1,122 | 1 payment
|
| Genentech | None | $660 | 1 payment
|
| Celgene | Opdualag | $544 | 11 payments
|
| Amgen | Blincyto | $167 | 4 payments
|
| Epizyme | Tazverik | $165 | 1 payment
|
| Astellas Pharma US | Xospata | $153 | 3 payments
|
| Gilead Sciences | Trodelvy | $132 | 2 payments
|
| Pfizer | Elrexfio | $116 | 2 payments
|
| Novartis Pharmaceuticals | Tasigna | $87 | 4 payments
|
| GlaxoSmithKline | Zejula | $65 | 3 payments
|
| Daiichi Sankyo | Enhertu | $54 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Iclusig | $51 | 2 payments
|
| Janssen Biotech | Darzalex | $40 | 3 payments
|
| Genzyme | Sarclisa | $38 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $28 | 1 payment
|
| Sobi | Doptelet | $19 | 1 payment
|
| Kite Pharma | None | $19 | 1 payment
|
| Lilly USA | Verzenio | $16 | 1 payment
|
| Regeneron Healthcare Solutions | Libtayo | $15 | 1 payment
|
2022: $35,971
| Genentech | Venclexta | $11,555 | 8 payments
|
| Acrotech Biopharma | Beleodaq | $6,503 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $4,393 | 17 payments
|
| Alexion Pharmaceuticals | Ultomiris | $3,745 | 5 payments
|
| Novartis Pharmaceuticals | Scemblix | $2,054 | 4 payments
|
| MorphoSys US | Monjuvi | $1,845 | 1 payment
|
| Abbvie | Venclexta | $1,702 | 3 payments
|
| Incyte | Monjuvi | $1,554 | 2 payments
|
| MorphoSys AG | Monjuvi | $1,293 | 1 payment
|
| Apellis Pharmaceuticals | None | $216 | 1 payment
|
| Kite Pharma | None | $160 | 4 payments
|
| Lilly USA | Cyramza | $132 | 2 payments
|
| Astellas Pharma US | Padcev | $118 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Iclusig | $114 | 2 payments
|
| Janssen Scientific Affairs | Darzalex | $103 | 1 payment
|
| Seagen | None | $100 | 1 payment
|
| ADC Therapeutics America | None | $99 | 1 payment
|
| Amgen | Lumakras | $97 | 2 payments
|
| Adaptive Biotechnologies | Clonoseq | $64 | 1 payment
|
| Daiichi Sankyo | Enhertu | $33 | 2 payments
|
| Genentech USA | Tecentriq | $32 | 3 payments
|
| Gilead Sciences | Trodelvy | $25 | 1 payment
|
| Pharmacosmos Therapeutics | Monoferric | $21 | 1 payment
|
| Pfizer | Bosulif | $12 | 1 payment
|
2021: $23,865
| Amgen | Blincyto | $4,626 | 4 payments
|
| Alexion Pharmaceuticals | Ultomiris | $4,077 | 5 payments
|
| MorphoSys AG | None | $2,976 | 2 payments
|
| Kite Pharma | Tecartus | $2,300 | 1 payment
|
| Genentech | None | $1,980 | 1 payment
|
| Janssen Scientific Affairs | None | $1,768 | 1 payment
|
| Karyopharm Therapeutics | Xpovio | $1,550 | 1 payment
|
| Janssen Global Services | None | $1,500 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $1,482 | 6 payments
|
| MorphoSys US | Monjuvi | $1,250 | 1 payment
|
| Genzyme | Cablivi | $153 | 2 payments
|
| Novartis Pharmaceuticals | Kymriah | $129 | 2 payments
|
| GlaxoSmithKline | Blenrep | $29 | 1 payment
|
| AbbVie | Creon | $18 | 1 payment
|
| Secura Bio | Farydak | $15 | 1 payment
|
| Acrotech Biopharma | Beleodaq | $12 | 1 payment
|
2020: $17,283
| Amgen | Blincyto | $6,408 | 4 payments
|
| Alexion Pharmaceuticals | Ultomiris | $4,295 | 4 payments
|
| Novartis Pharmaceuticals | Tasigna | $1,965 | 1 payment
|
| Pfizer | Bosulif | $1,769 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $1,626 | 13 payments
|
| Celgene | None | $904 | 1 payment
|
| Astellas Pharma US | Xospata | $112 | 3 payments
|
| Seagen | None | $95 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $60 | 1 payment
|
| Portola Pharmaceuticals | Andexxa | $18 | 1 payment
|
| Genentech USA | Tecentriq | $18 | 1 payment
|
| Karyopharm Therapeutics | Xpovio | $13 | 1 payment
|
2019: $43,701
| Astellas Pharma US | Xospata | $34,783 | 31 payments
|
| Novartis Pharmaceuticals | Tasigna | $6,781 | 4 payments
|
| Celgene | Revlimid | $1,467 | 5 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $246 | 51 payments
|
| Janssen Biotech | Darzalex | $216 | 24 payments
|
| Alexion Pharmaceuticals | Soliris | $72 | 1 payment
|
| Octapharma USA | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) | $63 | 1 payment
|
| Spectrum Pharmaceuticals | Folotyn | $24 | 1 payment
|
| Sun Pharmaceutical Industries | Odomzo | $22 | 1 payment
|
| Gilead Sciences | None | $15 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $12 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novartis Pharmaceuticals Corporation · A Phase II Multicenter, Open-Label, Single-Arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia · 2024 | Their institution | $2,463,699 |
| Novartis Pharmaceuticals Corporation · A Phase II Multicenter, Open-Label, Single-Arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia · 2025 | Their institution | $1,574,331 |
| Amgen Inc. · A Phase I/II Study of Blinatumomab in Combination With Pembrolizumab (Mk-3475) for Adults With Relapsed Or Refractory B-Lineage Acute Lymphoblastic Leukemia With High Bone Marrow Lymphoblast Percentage · 2021 | Their institution | $397,027 |
| PFIZER INC. · An Openlabel 3arm Multicenter Randomized Phase 3 Study To Evaluate the Efficacy and Safety of Elranatamab Pf06863135 Monotherapy and Elranatamab Daratumumab Versus Daratumumab Pomalidomide Dexamethasone in Participants With Relapsedrefractory Multiple Myeloma Who Have Received at Least 1 Prior Line of Therapy Including Lenalidomide and A Proteasome Inhibitor · 2024 | Their institution | $365,529 |
| PFIZER INC. · A Phase 3 Openlabel Study of Elranatamab Monotherapy Versus Elotuzumab Pomalidomide Dexamethasone Epd Or Pomalidomide Bortezomib Dexamethasone Pvd Or Carfilzomib Dexamethasone Kd in Participants With Relapsedrefractory Multiple Myeloma Who Received Prior Anticd38 Directed Therapy · 2025 | Their institution | $339,150 |
| PFIZER INC. · An Openlabel 3arm Multicenter Randomized Phase 3 Study To Evaluate the Efficacy and Safety of Elranatamab Pf06863135 Monotherapy and Elranatamab Daratumumab Versus Daratumumab Pomalidomide Dexamethasone in Participants With Relapsedrefractory Multiple Myeloma Who Have Received at Least 1 Prior Line of Therapy Including Lenalidomide and A Proteasome Inhibitor · 2023 | Their institution | $209,144 |
| PFIZER INC. · An Openlabel 3arm Multicenter Randomized Phase 3 Study To Evaluate the Efficacy and Safety of Elranatamab Pf06863135 Monotherapy and Elranatamab Daratumumab Versus Daratumumab Pomalidomide Dexamethasone in Participants With Relapsedrefractory Multiple Myeloma Who Have Received at Least 1 Prior Line of Therapy Including Lenalidomide and A Proteasome Inhibitor · 2025 | Their institution | $197,201 |
| Genentech, Inc. · Ph 3 Study of Glofitamab With Gemox Vs Rituximab With Gemox in Patients With R R Dlbcl · 2022 | Their institution | $169,096 |
| BeiGene, Ltd. · A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (Bgb-3111) Plus Anti-Cd20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular Or Marginal Zone Lymphoma · 2025 | Their institution | $144,479 |
| Novartis Pharmaceuticals Corporation · A Phase II Multicenter, Open-Label, Single-Arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia · 2023 | Their institution | $130,652 |
| BeOne Medicines USA, Inc. · A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (Bgb-3111) Plus Anti-Cd20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular Or Marginal Zone Lymphoma · 2025 | Their institution | $101,305 |
| Genentech, Inc. · Ph3 Study of Pola R Chp Glofit Vs Polar Chp in 1l Dlbcl · 2024 | Their institution | $86,163 |
| MorphoSys AG · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition To R-Chop Versus R-Chop in Previously Untreated, High-Intermediate and High-Risk Patients With Newly-Diagnosed Diffuse Large B-Cell Lymphoma (Dlbcl) · 2023 | Their institution | $80,968 |
| Genentech, Inc. · Ph3 Study of Pola R Chp Glofit Vs Polar Chp in 1l Dlbcl · 2025 | Their institution | $75,783 |
| Incyte Corporation · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition To R-Chop Versus R-Chop in Previously Untreated, High-Intermediate and High-Risk Patients With Newly-Diagnosed Diffuse Large B-Cell Lymphoma (Dlbcl), Front Mind · 2025 | Their institution | $74,612 |
| BeiGene, Ltd. · A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (Bgb 3111) Plus Anti-Cd20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular Or Marginal Zone Lymphoma · 2024 | Their institution | $69,620 |
| Celgene Corporation · A Phase 3, Open-Label, Randomized Study To Compare the Efficacy and Safety of Luspatercept (Ace-536) Vs Epoetin Alfa for the Treatment of Anemia Due To Revised International Prognostic Scoring System (Ipss-R) Very Low, Low, Or Intermediate Risk Myelodysplastic Syndrome (Mds) in Erythropoiesis-Stimulating Agent (Esa)-Naive Participants Who Are Non-Transfusion Dependent (Ntd): the Element-Mds Trial · 2025 | Their institution | $67,759 |
| MorphoSys AG · A Phase II/III, Randomised, Multicentre Study of Mor00208 With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma (R-R Dlbcl) Who Are Not Eligible for High-Dose Chemotherapy (Hdc) and Autologous Stem-Cell Transplantation (Asct) - B-Mind · 2022 | Their institution | $66,962 |
| Genentech, Inc. · Ph 3 Study of Glofitamab With Gemox Vs Rituximab With Gemox in Patients With R R Dlbcl · 2025 | Their institution | $53,680 |
| BeiGene USA, Inc. · A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (Bgb-3111) Plus Anti-Cd20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular Or Marginal Zone Lymphoma · 2025 | Their institution | $52,708 |
| Genentech, Inc. · Ph 3 Study of Glofitamab With Gemox Vs Rituximab With Gemox in Patients With R R Dlbcl · 2023 | Their institution | $51,618 |
| Janssen Research & Development, LLC · A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator'S Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (Epd) Or Pomalidomide, Borte · 2025 | Their institution | $50,691 |
| MorphoSys AG · An Observational Retrospective Cohort Study of Systemic Therapies for Relapsed Or Refractory Diffuse Large B Cell Lymphoma (R/R Dlbcl), To Compare Outcomes To Those From Tafasitamab + Lenalidomide in the L-Mind Study · 2021 | Their institution | $48,636 |
| E.R. Squibb & Sons, L.L.C. · A Phase 3, Open-Label, Randomized Study To Compare the Efficacy and Safety of Luspatercept Vs Epoetin Alfa for the Treatment of Anemia Due To Revised International Prognostic Scoring System Very Low, Low, Or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent Naive Participants Who Are Non-Transfusion Dependent · 2025 | Their institution | $44,798 |
| Incyte Corporation · A Phase II/III, Randomised, Multicentre Study of Mor00208 With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma (R-R Dlbcl) Who Are Not Eligible for High-Dose Chemotherapy (Hdc) and Autologous Stem-Cell Transplantation (Asct), B-Mind · 2025 | Their institution | $44,737 |
| ADC THERAPEUTICS AMERICA, INC. · A Study To Evaluate the Safety and Anti-Cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-Cancer Agents in Participants With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma (Lotis-7) · 2025 | Their institution | $42,573 |
| Janssen Research & Development, LLC · A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab Sc and Lenalidomide (Tec-Dr) Versus Daratumumab Sc, Lenalidomide, and Dexamethasone (Drd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible Or Not Intended for Autologous Stem Cell Transplant As Initial Therapy. · 2025 | Their institution | $39,517 |
| Epizyme, Inc. · Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat Or Placebo in Combination With Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma · 2023 | Their institution | $36,551 |
| ABBVIE INC. · A Study To Evaluate Adverse Events of Subcutaneous (Sc) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma · 2024 | Their institution | $35,385 |
| Epizyme, Inc. · Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat Or Placebo in Combination With Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma · 2024 | Their institution | $32,849 |
| Astellas Pharma Global Development · Randomized Trial of Gilteritinib Vs Midostaurin in Fl T3 Mutated Acute Myeloid Leukemia · 2021 | Their institution | $31,000 |
| MorphoSys AG · A Phase II/III, Randomised, Multicentre Study of Mor00208 With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma (R-R Dlbcl) Who Are Not Eligible for High-Dose Chemotherapy (Hdc) and Autologous Stem-Cell Transplantation (Asct) B-Mind · 2023 | Their institution | $30,071 |
| PFIZER INC. · A Phase 3 Openlabel Study of Elranatamab Monotherapy Versus Elotuzumab Pomalidomide Dexamethasone Epd Or Pomalidomide Bortezomib Dexamethasone Pvd Or Carfilzomib Dexamethasone Kd in Participants With Relapsedrefractory Multiple Myeloma Who Received Prior Anticd38 Directed Therapy · 2024 | Their institution | $27,926 |
| MorphoSys AG · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition To R-Chop Versus R-Chop in Previously Untreated, High-Intermediate and High-Risk Patients With Newly-Diagnosed Diffuse Large B-Cell Lymphoma (Dlbcl) - Front Mind · 2022 | Their institution | $25,669 |
| Epizyme, Inc. · Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat Or Placebo in Combination With Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma · 2025 | Their institution | $23,934 |
| Genentech, Inc. · Ph 3 Study of Glofitamab With Gemox Vs Rituximab With Gemox in Patients With R R Dlbcl · 2021 | Their institution | $21,109 |
| Celgene Corporation · A Study To Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (Mds) and Anemia Not Receiving Blood Transfusions - Ca056-025 · 2023 | Their institution | $18,948 |
| Incyte Corporation · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition To R-Chop Versus R-Chop in Previously Untreated, High-Intermediate and High-Risk Patients With Newly-Diagnosed Diffuse Large B-Cell Lymphoma (Dlbcl), Front Mind · 2024 | Their institution | $18,781 |
| Novartis Pharmaceuticals Corporation · A Phase III Randomized Double Blind Study of Induction Daunorubicin Cytarabine and Consolidation High Dose Cytarabine Chemotherapy Plus Midostaurin Pkc412 Or Placebo in Newly Diagnosed Patients With Flt3 Wild Type Flt3 Wt Acute Myeloid Leukemia Aml · 2020 | Their institution | $16,646 |
| BeOne Medicines Ltd. · A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (Bgb-3111) Plus Anti-Cd20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular Or Marginal Zone Lymphoma · 2025 | Their institution | $13,776 |
| Celgene Corporation · A Study To Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (Mds) and Anemia Not Receiving Blood Transfusions (Element-Mds) · 2024 | Their institution | $13,200 |
| E.R. Squibb & Sons, L.L.C. · Ph III Reblozyl Mds Ntd 1l · 2024 | Their institution | $12,188 |
| MorphoSys AG · A Phase II/III, Randomised, Multicentre Study of Mor00208 With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma (R-R Dlbcl) Who Are Not Eligible for High-Dose Chemotherapy (Hdc) and Autologous Stem-Cell Transplantation (Asct) - B-Mind · 2021 | Their institution | $11,572 |
| E.R. Squibb & Sons, L.L.C. · Ph I Hematology Ca210-003 · 2020 | Their institution | $11,566 |
| Karyopharm Therapeutics Inc. · A Phase 3 Randomized, Open-Label Trial of Selinexor, Pomalidomide, and Dexamethasone (Spd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (Elopd) in Patients With Relapsed Or Refractory Multiple Myeloma (Rrmm) · 2023 | Their institution | $11,154 |
| ABBVIE INC. · A Study To Evaluate Adverse Events of Subcutaneous (Sc) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma · 2025 | Their institution | $11,031 |
| Celgene Corporation · Phase I/Iia Iberdomide Nhl (PA C4d1) · 2023 | Their institution | $10,368 |
| E.R. Squibb & Sons, L.L.C. · Ph I Hematology Ca210-003 · 2019 | Their institution | $9,075 |
| Genentech, Inc. · Ph 3 Study of Glofitamab With Gemox Vs Rituximab With Gemox in Patients With R R Dlbcl · 2024 | Their institution | $8,558 |
| F. Hoffmann-La Roche AG · Ph 3 Study of Glofitamab With Gemox Vs Rituximab With Gemox in Patients With R R Dlbcl · 2024 | This clinician | $8,371 |
| AstraZeneca Pharmaceuticals LP · Treatment Patterns Outcomes and Patient Reported Quality of Life A Prospective Disease Registry of Patients With Mantle Cell Lymphoma Treated With Novel Agents · 2025 | Their institution | $7,946 |
| AstraZeneca Pharmaceuticals LP · Treatment Patterns Outcomes and Patient Reported Quality of Life A Prospective Disease Registry of Patients With Mantle Cell Lymphoma Treated With Novel Agents · 2021 | Their institution | $7,921 |
| F. Hoffmann-La Roche AG · Ph 3 Study of Glofitamab With Gemox Vs Rituximab With Gemox in Patients With R R Dlbcl · 2025 | This clinician | $7,419 |
| Incyte Corporation · A Phase II/III, Randomised, Multicentre Study of Mor00208 With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma (R-R Dlbcl) Who Are Not Eligible for High-Dose Chemotherapy (Hdc) and Autologous Stem-Cell Transplantation (Asct), B-Mind · 2024 | Their institution | $7,146 |
| E.R. Squibb & Sons, L.L.C. · Ph I Hematology Ca210-003 · 2021 | Their institution | $5,778 |
| Celgene Corporation · (Cc-486-Aml-001) Phiii Azacitidine + Best-Supportive Care Vs Best Supportive Care As Maintenance Therapy in Subjects With Aml in Complete Remission - Quazar · 2023 | Their institution | $5,670 |
| Celgene Corporation · Safety and Efficacy of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Subjects With Relapsed Or Refractory Multiple Myeloma (Cc-4047-Mm-007) · 2019 | Their institution | $5,544 |
| Astellas Pharma Global Development · Randomized Trial of Gilteritinib Vs Midostaurin in Fl T3 Mutated Acute Myeloid Leukemia · 2022 | Their institution | $5,000 |
| E.R. Squibb & Sons, L.L.C. · Ph I Hematology Ca210-003 · 2022 | Their institution | $4,350 |
| Acrotech Biopharma Inc. · Spi-Bel-301 · 2025 | This clinician | $2,633 |
| E.R. Squibb & Sons, L.L.C. · A Phase 3, Open-Label, Randomized Study To Compare the Efficacy and Safety of Luspatercept (Ace-536) Vs Epoetin Alfa for the Treatment of Anemia Due To Revised International Prognostic Scoring System (Ipss-R) Very Low, Low, Or Intermediate Risk Myelodysplastic Syndrome (Mds) in Erythropoiesis-Stimulating Agent (Esa)-Naive Participants Who Are Non-Transfusion Dependent (Ntd): the Element-Mds Trial · 2025 | Their institution | $2,250 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized, Open-Label, Phase 3 Trial of A+Avd Versus Abvd As Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma · 2024 | Their institution | $2,052 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized, Open-Label, Phase 3 Trial of A+Avd Versus Abvd As Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma · 2020 | Their institution | $1,636 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized, Open-Label, Phase 3 Trial of A+Avd Versus Abvd As Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma · 2025 | Their institution | $1,539 |
| Janssen Research & Development, LLC · A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator'S Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (Epd) Or Pomalidomide, Bortezomib, and Dexamethasone (Pvd) in Participants With Relapsed Or Refractory Myeloma Who Have Received 1 To 4 Prior Lines of Therapy Including An Anti-Cd38 Antibody and Lenalidomide · 2025 | Their institution | $1,373 |
| Celgene Corporation · Phiii Azacitidine Aml Quazar Cc-486-Aml-001 (Cc-486-Aml-001) · 2019 | Their institution | $1,260 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized, Open-Label, Phase 3 Trial of A+Avd Versus Abvd As Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma · 2019 | Their institution | $1,220 |
| AstraZeneca Pharmaceuticals LP · Treatment Patterns Outcomes and Patient Reported Quality of Life A Prospective Disease Registry of Patients With Mantle Cell Lymphoma Treated With Novel Agents · 2023 | Their institution | $1,192 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized, Open-Label, Phase 3 Trial of A+Avd Versus Abvd As Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma · 2021 | Their institution | $1,026 |
| AstraZeneca Pharmaceuticals LP · Treatment Patterns Outcomes and Patient Reported Quality of Life A Prospective Disease Registry of Patients With Mantle Cell Lymphoma Treated With Novel Agents · 2020 | Their institution | $964 |
| Novartis Pharmaceuticals Corporation · A Phase III Randomized Double Blind Study of Induction Daunorubicin Cytarabine and Consolidation High Dose Cytarabine Chemotherapy Plus Midostaurin Pkc412 Or Placebo in Newly Diagnosed Patients With Flt3 Wild Type Flt3 Wt Acute Myeloid Leukemia Aml · 2019 | Their institution | $923 |
| MorphoSys, US Inc. · A Phase II/III, Randomised, Multicentre Study of Mor00208 With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma (R-R Dlbcl) Who Are Not Eligible for High-Dose Chemotherapy (Hdc) and Autologous Stem-Cell Transplantation (Asct) ? B-Mind · 2024 | Their institution | $641 |
| AstraZeneca Pharmaceuticals LP · Treatment Patterns Outcomes and Patient Reported Quality of Life A Prospective Disease Registry of Patients With Mantle Cell Lymphoma Treated With Novel Agents · 2024 | Their institution | $596 |
| AstraZeneca Pharmaceuticals LP · Treatment Patterns Outcomes and Patient Reported Quality of Life A Prospective Disease Registry of Patients With Mantle Cell Lymphoma Treated With Novel Agents · 2022 | Their institution | $596 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized, Open-Label, Phase 3 Trial of A+Avd Versus Abvd As Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma · 2023 | Their institution | $513 |
| Novartis Pharmaceuticals Corporation · Cabl001aus08 · 2025 | This clinician | $360 |
| Novartis Pharmaceuticals Corporation · Research Publication/ Writing Support · 2025 | This clinician | $333 |
| AstraZeneca UK Limited · Treatment Patterns Outcomes and Patient Reported Quality of Life A Prospective Disease Registry of Patients With Mantle Cell Lymphoma Treated With Novel Agents · 2022 | Their institution | $298 |
| ABBVIE INC. · M23-362 Ph2 Epcoritamab Rr Dlbcl and Fl Outpatient Study · 2024 | Their institution | $176 |
| Epizyme, Inc., · A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat Or Placebo in Combination With Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma · 2022 | Their institution | $79 |
| ABBVIE INC. · A Phase 2, Open-Label Trial To Evaluate Safety of Epcoritamab Monotherapy in Subjects With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) When Administered in the Outpatient Setting · 2025 | Their institution | $24 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 84.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1508024647
- Licence
- CA A111931California A111931: Current · expires 2028-01-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X); Internal medicine (207R00000X); Federal specialty code 207RH0000X (207RH0000X); Medical oncology (207RX0202X)
- Mailing address
- 2625 E Divisadero St, Fresno, CA, 93721
- NPI first listed
- 2008-05-27
- NPI last updated
- 2021-01-27
- NPI record certified
- 2021-01-27
This is when the NPI record was last certified, not a medical board exam.